Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification

(2017) Aurel Perren et al.   NEUROENDOCRINOLOGY

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE

(2016) Maddalena Sansovini et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms

(2015) Olca Basturk et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas

(2015) V. Ambrosini et al.   JOURNAL OF NUCLEAR MEDICINE

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy

(2015) Phillip G. Claringbold et al.   NEUROENDOCRINOLOGY

Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system

(2014) Tomohiro Yamaguchi et al.   CANCER SCIENCE

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study

(2014) Giovanni Paganelli et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

(2014) Raghava Kashyap et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors

(2014) C. Kratochwil et al.   MOLECULAR IMAGING AND BIOLOGY

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

(2013) Fritz-Line Vélayoudom-Céphise et al.   ENDOCRINE-RELATED CANCER

Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours

(2013) Stefano Severi et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas

(2013) Z. H. Lu et al.   MEDICAL ONCOLOGY

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

(2012) H. Sorbye et al.   ANNALS OF ONCOLOGY

18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors

(2010) T. Binderup et al.   CLINICAL CANCER RESEARCH

Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas

(2010) S. Iwasa et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Expression of Somatostatin and Dopamine 2 Receptors in Neuroendocrine Tumours and the Potential Role for New Biotherapies

(2009) R. Srirajaskanthan et al.   NEUROENDOCRINOLOGY

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastroenteropancreatic neuroendocrine tumours

(2008) Irvin M Modlin et al.   LANCET ONCOLOGY